Next Article in Journal
Preoperative and Postoperative Assessment of Ultrasonographic Measurement of Inferior Vena Cava: A Prospective, Observational Study
Next Article in Special Issue
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
Previous Article in Journal
Platelet-Rich Plasma May Offer a New Hope in Suppressed Wound Healing When Compared to Mesenchymal Stem Cells
Previous Article in Special Issue
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study
Open AccessReview

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

1
INSERM UMR-S1147, Paris Sorbonne Cite University, 75270 Paris Cedex 06, France
2
Department of Biochemistry, Unit of Pharmacogenetics and Molecular Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(6), 144; https://doi.org/10.3390/jcm7060144
Received: 24 May 2018 / Revised: 5 June 2018 / Accepted: 6 June 2018 / Published: 9 June 2018
Recent changes in lung cancer care, including new approvals in first line and the introduction of high-throughput molecular technologies in routine testing led us to question ourselves on how deeper molecular testing may be helpful for the optimal use of targeted drugs. In this article, we review recent results in the scope of personalized medicine in lung cancer. We discuss biomarkers that have a therapeutic predictive value in lung cancer with a focus on recent changes and on the clinical value of large scale sequencing strategies. We review the use of second- and third-generation EGFR and ALK inhibitors with a focus on secondary resistance alterations. We discuss anti-BRAF and anti-MEK combo, emerging biomarkers as NRG1 and NTRKs fusions and immunotherapy. Finally, we discuss the different technical issues of comprehensive molecular profiling and show how large screenings might refine the prediction value of individual markers. Based on a review of recent publications (2012–2018), we address promising approaches for the treatment of patients with lung cancers and the technical challenges associated with the identification of new predictive markers. View Full-Text
Keywords: lung cancer; molecular analysis; NGS; oncogene drivers lung cancer; molecular analysis; NGS; oncogene drivers
Show Figures

Figure 1

MDPI and ACS Style

Garinet, S.; Laurent-Puig, P.; Blons, H.; Oudart, J.-B. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J. Clin. Med. 2018, 7, 144.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop